For Indian billionaire Dilip Shanghvi, who made his fortune selling cheap generic drugs to the world, it was clear at least more than a decade ago that a shift toward specialty treatments would be key to success in the crowded local market.
Last week, his firm Sun Pharmaceutical Industries Ltd. announced a $12 billion deal that could be the biggest test yet in the company’s long-brewing bid to transform into an international giant. The company agreed to acquire New Jersey-based Organon & Co. in an all-cash deal that marks one of India’s largest global takeovers and challenges Shanghvi to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
